Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2009-04-06
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 719
- Registration Number
- NCT00876395
- Locations
- ๐บ๐ธ
Comprehensive Blood and Cancer Center Dept. of CBCC (2), Bakersfield, California, United States
๐บ๐ธNew York Oncology Hematology NYOH Amsterdam, Albany, New York, United States
๐บ๐ธTexas Oncology Charles A. Sammons Cancer Ctr, Dallas, Texas, United States
Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study
- Conditions
- Non-transfusion Dependent Thalassemia
- Interventions
- Drug: placebo
- First Posted Date
- 2009-04-01
- Last Posted Date
- 2013-07-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 166
- Registration Number
- NCT00873041
- Locations
- ๐บ๐ธ
Children's Memorial Hospital/Division of Hematology/Oncology, Chicago, Illinois, United States
๐บ๐ธNew York Presbyterian Hospital/Weill Medical College of Cornell University, New York, New York, United States
๐บ๐ธChildren's Hospital & Research Center Oakland, Oakland, California, United States
Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma
- First Posted Date
- 2009-03-27
- Last Posted Date
- 2011-11-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 271
- Registration Number
- NCT00870584
- Locations
- ๐บ๐ธ
Palm Spring Research Institute, Inc, Hialeah, Florida, United States
๐บ๐ธPaul A Shapero, MD, Bangor, Maine, United States
๐บ๐ธPediatric Pulmonary Associates of North Texas, PA, Dallas, Texas, United States
Five Year Adjuvant Imatinib Mesylate (Gleevecยฎ) in Gastrointestinal Stromal Tumor (GIST)
- First Posted Date
- 2009-03-23
- Last Posted Date
- 2018-03-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 91
- Registration Number
- NCT00867113
- Locations
- ๐บ๐ธ
Washington Hospital Center Department of Medical Oncology, Washington, District of Columbia, United States
๐บ๐ธLongstreet Cancer Center, Gainesville, Georgia, United States
๐บ๐ธPenn State University / Milton S. Hershey Medical Center Penn Stat University, Hershey, Pennsylvania, United States
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- First Posted Date
- 2009-03-20
- Last Posted Date
- 2021-02-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 940
- Registration Number
- NCT00866697
- Locations
- ๐จ๐ณ
Novartis Investigative Site, Taipei, Taiwan
A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia
- Conditions
- Acute Lymphoblastic LeukemiaAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2009-03-20
- Last Posted Date
- 2015-12-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 22
- Registration Number
- NCT00866281
- Locations
- ๐บ๐ธ
Seattle Children's Hospital CPKC412A2114, Seattle, Washington, United States
๐ธ๐ชNovartis Investigative Site, Stockholm, Sweden
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2009-03-18
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 724
- Registration Number
- NCT00863655
- Locations
- ๐บ๐ธ
University of Texas Southwestern Medical Center SimmonsComprehensiveCancerCtr., Dallas, Texas, United States
๐บ๐ธMercy Medical Center Medical Oncology & Hematology, Baltimore, Maryland, United States
๐บ๐ธCrescent City Research Consortium, LLC Dept of Hem&Onc Specialist - 2, Metairie, Louisiana, United States
Efficacy of Telbivudine in Blacks/African Americans and Hispanics/Latinos With Compensated Chronic Hepatitis B During 52 Weeks
- Conditions
- Compensated Chronic Hepatitis B
- Interventions
- Drug: Telbivudine/LDT600A
- First Posted Date
- 2009-03-17
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT00862706
- Locations
- ๐บ๐ธ
Liver Specialist of Texas, Houston, Texas, United States
๐บ๐ธTufts Medical Center, Boston, Massachusetts, United States
๐บ๐ธHepatobiliary Associates of New York, Bayside, New York, United States
A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients
- Conditions
- Heart Transplantation
- Interventions
- First Posted Date
- 2009-03-17
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 162
- Registration Number
- NCT00862979
- Locations
- ๐ฉ๐ช
Novartis Investigative Site, Regensburg, Germany
Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2009-03-12
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1988
- Registration Number
- NCT00860288
- Locations
- ๐ฐ๐ท
Ajou university hospital, Suwon, Korea, Republic of
๐ฑ๐ปDaugavpils Regional Hospital, Daugavpils, Latvia
๐ฑ๐ปTalsi Clinical Hospital, Talsi, Latvia